Methods of treating hypertension in obese subjects
AssigneeMineralys Therapeutics, Inc.
InventorsDavid Rodman, Jon Congleton
Life of this patent
Estimating the term…
Abstract
This invention provides a method of treating hypertension in a hypertensive subject having a body mass index of at least 30, the method comprising administering to the subject a CYP 11β2 beta hydroxylase inhibitor once or twice per day in an amount sufficient to treat hypertension in the hypertensive subject.
Claims29
A method of treating hypertension in a hypertensive subject having a body mass index of at least 30, the method comprising administering to the subject a CYP 11β2 beta hydroxylase inhibitor once or twice per day in an amount sufficient to treat hypertension in the hypertensive subject.
A method of treating hypertension in a male hypertensive subject having a waist-hip ratio above 0.90, or in a female hypertensive subject having a waist-hip ratio above 0.85, the method comprising administering to the subject a CYP 11β2 beta hydroxylase inhibitor once or twice per day in an amount sufficient to treat hypertension in the hypertensive subject.
A method of treating hypertension in a hypertensive subject having a body mass index of more than 30, preferably 30-50, more preferably 30-40, the method comprising administering to the subject a CYP 11β2 beta hydroxylase inhibitor once or twice per day in an amount sufficient to treat hypertension in the hypertensive subject.
A method of treating hypertension in a hypertensive subject having a serum leptin concentration of at least 30 ng/dL, preferably at least 35 ng/dL, more preferably at least 40 ng/dL, or more preferably 30-50 ng/dL, 30-45 ng/dL, or 35-50 ng/dL, the method comprising administering to the subject a CYP 11β2 beta hydroxylase inhibitor once or twice per day in an amount sufficient to treat hypertension in the hypertensive subject.
A method of treating hypertension in a hypertensive subject in need thereof, the method comprising
- a) measuring
- i) a systolic blood pressure of greater than 130 mmHg in said subject;
- ii) a diastolic BP of greater than 80 mmHg in said subject;
- and
- iii) a body mass index (BMI) of at least 30, preferably 30-50, more preferably 30-40, in said subject, or a waist-hip ratio above 0.90 in said subject if the hypertensive subject is male, or a waist-hip ratio above 0.85 in said subject if the hypertensive subject is female;
- and
- b) administering to said subject an effective amount of a CYP 11β2 beta hydroxylase inhibitor.
A method of treating hypertension in a hypertensive subject in need thereof, the method comprising
- a) measuring in said hypertensive subject
- i) a systolic blood pressure of greater than 130 mmHg;
- ii) a diastolic BP of greater than 80 mmHg;
- and
- iii) one or more or all of the following:
- (1) a body mass index (BMI) of at least 30, preferably more than 30, preferably 30-50, more preferably 30-40;
- (2) a waist-hip ratio above 0.90 if the hypertensive subject is male or a waist-hip ratio above 0.85 if the hypertensive subject is female;
- and
- (3) a serum leptin of at least 30 ng/dL, preferably at least 35 ng/dL, more preferably at least 40 ng/dL, or more preferably 30-50 ng/dL, 30-45 ng/dL, or 35-50 ng/dL;
- and
- b) administering to said subject an effective amount of a CYP 11β2 beta hydroxylase inhibitor.
A method of treating hypertension in a hypertensive subject in need thereof, the method comprising
- a) receiving an identification of the hypertensive subject as having
- i) a systolic blood pressure of greater than 130 mmHg;
- ii) a diastolic BP of greater than 80 mmHg;
- and
- iii) one or more or all of the following:
- (1) a body mass index (BMI) of at least 30, preferably more than 30, preferably 30-50, more preferably 30-40;
- (2) a waist-hip ratio above 0.90 if the hypertensive subject is male or a waist-hip ratio above 0.85 if the hypertensive subject is female;
- and
- (3) a serum leptin of at least 30 ng/dL, preferably at least 35 ng/dL, more preferably at least 40 ng/dL, or more preferably 30-50 ng/dL, 30-45 ng/dL, or 35-50 ng/dL;
- and
- b) administering to said subject an effective amount of a CYP 11β2 beta hydroxylase inhibitor.
A method of identifying a subject for hypertension treatment with a CYP 11β2 beta hydroxylase inhibitor, the method comprising:
- a) measuring a systolic blood pressure of greater than 130 mmHg in said subject;
- b) measuring a diastolic BP of greater than 80 mmHg in said subject;
- and
- c) measuring a body mass index (BMI) of at least 30, preferably 30-50, more preferably 30-40, in said subject, or measuring a waist-hip ratio above 0.90 in said subject if the subject is male, or measuring a waist-hip ratio above 0.85 in said subject if the subject is female;
- thereby identifying said subject for hypertension treatment with a CYP 11β2 beta hydroxylase inhibitor.
A method of identifying a subject for hypertension treatment with a CYP 11β2 beta hydroxylase inhibitor, the method comprising:
- a) measuring a systolic blood pressure of greater than 130 mmHg in said subject;
- b) measuring a diastolic BP of greater than 80 mmHg in said subject;
- and
- c) measuring one or more or all of the following in said subject:
- i) a body mass index (BMI) of at least 30, preferably 30-50, more preferably 30-40;
- ii) a waist-hip ratio above 0.90 if the subject is male or a waist-hip ratio above 0.85 if the subject is female;
- and
- iii) a serum leptin concentration of at least 30 ng/dL, preferably at least 35 ng/dL, more preferably at least 40 ng/dL, or more preferably 30-50 ng/dL, 30-45 ng/dL, or 35-50 ng/dL;
- thereby identifying said subject for hypertension treatment with a CYP 11β2 beta hydroxylase inhibitor.
Dependencies are inferred from the claim text.